Table 1 Patient characteristics

n

24

16

40

female:male

21:3

3:13

24:16

age (mean±SD)(range), years

53.2±7.4 (35-77)

42.1±10.9 (24-72)

51.5±13.6 (24-77)

age at diagnosis (mean±SD)(range), years

43.5±11.6 (29-58)

29.2±8.9 (17-44)

42.1±13.5 (17-58)

disease duration (mean±SD) (range), years

8.7±8.5 (1-44)

7.0±6.7 (1-26)

8.3±7.8 (1-44)

RF positivity, n (%)

17 (71)

-

-

ACPA positivity, n (%)

14 (58)

-

-

DAS28 (baseline) (mean±SD)

4.92±1.12

-

-

BASDAI (baseline) (mean±SD)

-

5.66±1.33

-

Treatment (ETN, CZP)

14 ETN, 10 CZP

16 ETN

30 ETN, 10 CZP

Low-dose corticosteroids (< 6 mg/day methylprednisone)

8

1

9

DXA L2-L4 osteoporosis (T-score <-2.5)

2

1

3

DXA L2-L4 osteopenia (T-score<-1)

12

2

14

DXA femoral neck osteoporosis (T-score<-2.5)

1

1

2

DXA femoral neck osteopenia (T-score<-1)

11

5

16

fragility fracture history

7

6

13